drugset / Trial / NCT06955741

A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants

NCT06955741

Phase 1 Completed 46 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess drug levels, tolerability and absolute biological availability of single subcutaneous dose of BMS-986446 in healthy participants

Timeline

Start
2025-05-05
Primary completion
2025-09-11
Completion
2025-09-11

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986446 Monoclonal antibody Intravenous
Background Acetaminophen Small molecule
Background Loratadine Small molecule

Indications

No indication recorded.